Two of the most familiar toxins have never been directly compared in a rigorous trial, until now. At a May conference, Ipsen presented the first randomized, double-blind head-to-head of Dysport versus Botox.
At the SCALE 2026 conference in May, Ipsen presented late-breaking data from what was described as the first randomized, double-blind head-to-head study directly comparing Dysport and Botox for frown lines, a comparison the field had long lacked. Full peer-reviewed results were still pending, so conclusions should await complete publication.
Patients and providers constantly debate which toxin is better, yet rigorous direct comparisons have been surprisingly rare.
May brought a notable step toward an evidence-based answer.
Alongside its corabotase data at the SCALE 2026 conference, Ipsen presented late-breaking results from a randomized, double-blind study comparing Dysport (abobotulinumtoxinA) directly with Botox (onabotulinumtoxinA) for glabellar (frown) lines. Described as a first-of-its-kind head-to-head, the study addresses a long-standing gap: although both toxins are widely used, direct, controlled comparisons between them have been limited, leaving much of the everyday better-than debate to indirect data and clinical impression.
As of the May presentation, full peer-reviewed results were still pending. Conference presentations are early communications, and details such as dosing equivalence and endpoints matter enormously when comparing toxins. The responsible read is that a meaningful comparison is underway, but firm conclusions should wait for the complete, peer-reviewed publication.
For consumers, a credible head-to-head could eventually inform conversations about which toxin suits a given goal, but it will not crown a universal winner. Toxins differ in dosing units, spread, and onset, and individual response varies. The practical implication is that even strong comparative data supports provider judgment rather than replacing it, and the right choice still depends on the patient, the area treated, and the injector experience.
Watch for the full peer-reviewed publication, including how doses were matched and which outcomes were measured, the details that determine whether a comparison is fair and actionable. Independent analysis will matter, given the sponsor is a maker of one of the products. For patients, the steady guidance is unchanged: choose a qualified injector and an FDA-approved toxin appropriate for your goal, rather than over-reading a single conference headline.